Blog
RSS FeedPosted by Michael Wonder on 04 Mar 2022
Hundreds of patients to benefit from revolutionary lung cancer drug on the NHS
3 March 2022 - A revolutionary targeted drug for lung cancer will be made available to anyone who is eligible, ...
Posted by Michael Wonder on 01 Mar 2022
ABPI response to England Rare Diseases Action Plan
28 February 2022 - England's Rare Disease Action plan is published today with details of how to improve diagnosis, care and ...
Posted by Michael Wonder on 27 Feb 2022
NHS treats first sickle cell disease patients with life changing drug
24 February 2022 - One of the first patients to access a ground-breaking treatment for sickle cell disease on the ...
Posted by Michael Wonder on 13 Feb 2022
First young children now taking life changing cystic fibrosis treatment on NHS
12 February 2022 - One of the first children to receive the game changing cystic fibrosis treatment, Kaftrio, on the ...
Posted by Michael Wonder on 10 Feb 2022
New life-extending drug for advanced womb cancer to be rolled out on the NHS
8 February 2022 - A 30 minute treatment, the first of its kind for advanced womb cancer, is being rolled ...
Posted by Michael Wonder on 07 Feb 2022
Not so NICE: cancer patients miss out on innovative new treatments
7 February 2022 - Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes ...
Posted by Michael Wonder on 02 Feb 2022
Equity in cancer drug access in the UK
1 February 2022 - In draft guidance published on 5 January 2022, NICE announced their decision not to recommend the use ...
Posted by Michael Wonder on 24 Jan 2022
Patients to receive new cancer drugs faster under Brexit rules shake-up
23 January 2022 - Seven medicines already approved as changes cut as much as a month off approval times. ...
Posted by Michael Wonder on 20 Oct 2021
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges
20 October 2021 - Medical devices are potentially good candidates for coverage with evidence development schemes, as clinical data at market ...
Posted by Michael Wonder on 21 Sep 2021
NHS patients gain access to COVID-19 treatment Ronapreve
21 September 2021 - The UK has secured supply of Ronapreve, a new COVID-19 therapeutic developed by Regeneron and Roche ...
Posted by Michael Wonder on 12 Sep 2021
NHS lung cancer patients in England get early access to ‘breakthrough’ cancer drug
10 September 2021 - The MHRA has approved a first-of-its-kind cancer drug – capable of targeting a gene mutation that ...
Posted by Michael Wonder on 18 Aug 2021
MS drug: Hull couple's treatment denied by 'cruel' postcode lottery
18 August 2021 - A couple who both have multiple sclerosis say they are being denied a drug which could ...
Posted by Michael Wonder on 10 Aug 2021
‘Life-changing’ MS drug costs £600 a month in England but is free on NHS in Scotland
9 August 2021 - Multiple sclerosis patients in England are paying £600 a month for a “life-changing drug” which is ...
Posted by Michael Wonder on 16 Jul 2021
NICE’s decision not to approve Zytiga ‘frustrating’, says ICR
16 July 2021 - NICE has decided not to recommend Janssen’s Zytiga after reviewing its previous decision to reject the ...
Posted by Michael Wonder on 26 May 2021
Colchester baby's parents feel 'abandoned' over £1.7 million drug
25 May 2021 - A baby with a fatal genetic condition has been "abandoned" in a "race against time" for ...